Application of rapamycin or tumor necrosis factor alpha in preventing and/or treating diseases associated with mesenchymal stem cell injury

A mesenchymal stem cell, rapamycin technology, applied in the prevention and/or treatment of diseases related to mesenchymal stem cell damage, rapamycin or tumor necrosis factor α, can solve problems such as ignorance and affecting BMMSC function , achieve the effect of improving function, reducing bone loss and reducing bone density

Pending Publication Date: 2021-04-13
施松涛
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is not known whether and how these MSC-derived cytokines affect BMMSC function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rapamycin or tumor necrosis factor alpha in preventing and/or treating diseases associated with mesenchymal stem cell injury
  • Application of rapamycin or tumor necrosis factor alpha in preventing and/or treating diseases associated with mesenchymal stem cell injury
  • Application of rapamycin or tumor necrosis factor alpha in preventing and/or treating diseases associated with mesenchymal stem cell injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] The general experimental method that embodiment 1 present invention relates to

[0090] 1. Experimental materials

[0091] (1) ANIMAL. Female C57BL / 6J and B6.129S-Tnftm1Gk1 / J (TNFα- / -), B6.129S7-Ifngtm1Ts / J (IFNγ- / -), B6.129S2-Il6tm1Kopf / J (IL-6- / -), B6 .129S-TNFαsf1atm1ImxTNFαsf1btm1Imx / J(TNFα- / -), B6.Cg-Tg(Prrx1-cre)1Cjt / J(Prx1-Cre) and B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze / J Mice were purchased from Jackson Lab and maintained at least 10 backcrosses in the C57BL / 6J background. Age-matched female littermates were used in all experiments. Female immunocompromised nude mice (Beige nu / nuXIDIII) were purchased from Harlan.

[0092] (2) Animal model, that is, hindlimb unloading. Mice were randomly divided into three groups: control group, unloading group and rapamycin-treated group. Mice in the unloaded group were subjected to continuous hindlimb suspension for 2 weeks. Hindlimb unloading was performed as previously described (Egawa et al., 2015). Briefly, the ta...

Embodiment 2

[0110] Example 2. TNFα is required to maintain BMMSC homeostasis through a TNF receptor-independent pathway.

[0111] 1. Experimental materials

[0112] (1) ANIMAL. Please refer to the experimental materials in Part 1 of Example 1.

[0113] 2. Experimental method

[0114] Please refer to the experimental method (1)-(15) of the second part of Example 1.

[0115] 3. Experimental results

[0116] To examine whether MSC-produced cytokines could modulate stem cell properties in BMMSCs, TNFα knockout (TNFα- / -), interferon-γ knockout (IFNγ- / -) and interleukin-6 knockout (IL- 6- / -) mice were used as a cytokine-deficient model to examine BMMSC function. found that TNFα- / -, but not IFNγ- / - and IL-6- / -, BMMSCs showed significantly reduced colony-forming unit fibroblast numbers (CFU-F; figure 1 A and Figure 8 A) and significantly reduced proliferation rate as assessed by toluidine blue staining and BrdU labeling assays, respectively ( figure 1 B and Figure 8 B). When cultured ...

Embodiment 3

[0122] Example 3. Endocytic TNFα inhibits mTOR activation by binding to mTOR complex 2.

[0123] 1. Experimental materials

[0124] (1) ANIMAL. Please refer to the experimental materials in Part 1 of Example 1.

[0125] 2. Experimental method

[0126] Please refer to the experimental method (1)-(15) of the second part of Example 1.

[0127] 3. Experimental results

[0128] Since TNFα protein was detected in TNFα- / - BMMSC lysates after mTNFα treatment, as analyzed by Western blot ( Figure 9 B and 3B) Assessed, it is hypothesized that mTNF[alpha] can be internalized by endocytosis. To test this hypothesis, TNFα- / - BMMSCs were treated with FITC-tagged mTNFα (FITC-TNFα), followed by immunofluorescence (IF) microscopy to detect FITC-TNFα in the cytoplasm; it mainly surrounds the nuclear region ( image 3 A). Furthermore, FITC-tagged TNFα was detected in TNFα- / - BMMSCs, suggesting that TNFα endocytosis is independent of TNF receptors ( image 3 A). Next, apply the CMst inh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to prevention and treatment of diseases associated with mesenchymal stem cell injury. The invention relates to application of rapamycin or a tumor necrosis factor alpha in preventing and/or treating diseases associated with mesenchymal stem cell injury.

Description

technical field [0001] The present invention relates to the field of prevention and / or treatment of diseases related to damage of mesenchymal stem cells. Specifically, the present invention relates to the use of rapamycin or tumor necrosis factor alpha (TNFα) for the prevention and / or treatment of diseases associated with mesenchymal stem cell damage. Background technique [0002] TNFα is a pro-inflammatory cytokine responsible for immune regulation through its receptor-mediated signaling. Originally discovered as a factor associated with killing tumor cells, TNFα is a proinflammatory cytokine responsible for immune regulation (Beutler et al., 1985; Carswell et al., 1975; Kelker et al., 1985; Malaviya et al., 1996; Pennica et al., 1984). Transmembrane TNFα, also known as precursor TNFα (pro-TNFα), is a 26 kDa protein expressed on the cell surface of monocytes / macrophages, NK cells, activated T cells and various non-immune cells such as endothelial cells. Pro-TNFα is cleave...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/436A61K38/19A61P19/10
CPCA61K31/436A61K38/191A61P19/10
Inventor 施松涛
Owner 施松涛
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap